02:05 , Aug 26, 2015 |  BC Extra  |  Clinical News

Two studies support new universal flu vaccine approach

Separate studies published in Science and Nature Medicine provide proof of concept for a new universal influenza vaccine strategy. The papers show stabilized forms of the hemagglutinin stem, a highly conserved region of the influenza...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Clinical News

H5N1 VLP vaccine: Phase II started

Medicago began a placebo-controlled Phase II trial to evaluate its intramuscular H5N1 VLP vaccine plus an alum adjuvant or Glucopyranosyl Lipid A (GLA-AF) adjuvant in 390 healthy adults ages 18-60 years. Medicago Inc. (TSX:MDG; OTCQX:MDCGF),...
07:00 , May 13, 2013 |  BC Week In Review  |  Clinical News

H5N1 VLP vaccine: Interim Phase I data

Interim data from a single-blind, U.S. Phase I trial in 100 healthy volunteers aged 18-49 years showed that a 20 µg dose of the H5N1 VLP vaccine plus 2.5 µg intradermal Glucopyranosyl Lipid A (GLA-AF)...
08:00 , Dec 20, 2012 |  BC Innovations  |  Cover Story

Translating mRNA vaccines

A collaboration between CureVac GmbH and the Friedrich Loeffler Institute has produced in vivo evidence that an mRNA-based vaccine can prevent influenza A infection. 1 The results provide proof of concept for the company's vaccine...
07:00 , Aug 20, 2012 |  BC Week In Review  |  Clinical News

H5N1 VLP vaccine: Phase I start

Next month, not-for-profit Infectious Disease Research Institute (IDRI) (Seattle, Wash.) will begin a U.S. Phase I trial to compare 2 intradermal and intramuscular injections of 20 µg H5N1 VLP vaccine from Medicago plus 2.5 µg...
07:00 , May 21, 2012 |  BC Week In Review  |  Clinical News

FluGEM: Phase I data

A single-blind, Dutch Phase I trial in 60 healthy volunteers aged 18-49 showed that intranasal FluGEM was well tolerated with a rate of overall adverse events comparable to that of standard trivalent split influenza antigen....
07:00 , May 21, 2012 |  BC Week In Review  |  Clinical News

Mucosis preclinical data

In mice, Mucosis' FluGEM vaccine provided full protection against homologous and heterologous influenza infection, with a 300-fold reduction in viral titers in the lungs vs. conventional influenza vaccination. Data were published in Vaccine. FluGEM is...
07:00 , Apr 12, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Combinatorial libraries for unbiased identification of CD8+ T cell target antigens Combinatorial libraries of short peptides could help identify CD8+ T cell antigens and...
07:00 , Aug 22, 2011 |  BC Week In Review  |  Clinical News

Fludase: Phase II data

Top-line data from a double-blind, U.S. Phase II trial in 177 evaluable patients with PCR-confirmed influenza infection showed that once-daily 10 mg DAS181 for 3 days significantly reduced viral load in respiratory secretions, the primary...
07:00 , Jul 25, 2011 |  BC Week In Review  |  Clinical News

VGX-3400: Phase I data

An open-label, dose-escalation, U.S. and Korean Phase I trial in 60 healthy volunteers showed that 2 intramuscular injections of 0.2, 0.67 or 2 mg VGX-3400X delivered by Inovio's CELLECTRA electroporation system were well tolerated with...